

1. Record Nr.	UNINA9910780628203321
Titolo	Endocrine therapies in breast cancer [[electronic resource] /] / edited by Aman U. Buzdar
Pubbl/distr/stampa	Oxford ; ; New York, : Oxford University Press, 2007
ISBN	0-19-173987-1 0-19-960699-4 1-283-58075-6 9786613893208 0-19-157517-8
Descrizione fisica	1 online resource (129 p.)
Collana	Oxford oncology library
Altri autori (Persone)	BuzdarAman U
Disciplina	616.99/449071
Soggetti	Breast - Cancer - Hormone therapy Breast - Cancer - Endocrine aspects
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Contents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; Z
Sommario/riassunto	Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging